Home > Haematology > EHA 2021 > Letter from the Editor

Letter from the Editor

Prof. Gert Ossenkoppele, Amsterdam UMC, the Netherlands
EHA 2021
Dear Reader, It is my pleasure to introduce this peer-reviewed EHA 2021 Medicom Conference Report. We all miss the in-person meetings due to the COVID-19 pandemic. This year’s annual EHA meeting also had to be held virtually. Nevertheless, the Scientific Program Committee of the EHA has taken care of what, in my opinion, turned out to be a wonderful programme. From this year’s EHA, we selected a number of interesting abstracts that are likely to change your practice now or in the near future. The abstracts are summarised in a way that the information is easy to digest in a rather short time. The increase of abstracts we have observed at previous meetings on immunotherapy including bispecific antibody and CAR T-cell treatment applied in a variety of haematological malignancies was maintained. Also, gene therapy is now rapidly moving from bench to bedside, resulting in new treatments for haemoglobinopathies and haemophilia. Treatment of AML, a disease in which ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on